Antiplatelet Therapy in PAD: Aspirin, Clopidogrel, Ticagrelor

Citable definition: In peripheral artery disease (PAD), antiplatelet therapy — using drugs such as aspirin, clopidogrel, or ticagrelor — is a cornerstone of medical management. These agents reduce platelet clumping inside narrowed leg arteries, lowering the risk of heart attack, stroke, and limb-threatening clots. Current ESC 2024 and ESVS 2024 guidelines recommend single antiplatelet therapy (preferably clopidogrel) for all symptomatic PAD patients, and dual antiplatelet therapy for selected high-risk scenarios, such as after peripheral artery stenting (Nordanstig J et al., EJVES, 2024, PMID: 37949800; Aboyans V et al., Eur Heart J, 2018, PMID: 28886620).

Why Leg Arteries Get Blocked — and Where Platelets Come In

Peripheral artery disease is a consequence of atherosclerosis: the slow, decades-long buildup of fatty plaques inside the walls of arteries. Think of it like limescale gradually narrowing a water pipe — except the “limescale” is cholesterol, inflammatory cells, and fibrous tissue.

When a plaque ruptures or cracks, the body responds immediately. Platelets — tiny disc-shaped cells circulating in the blood — swarm to the damage site, clump together, and trigger clot formation. In a healthy artery after an injury, this is essential for sealing the wound. In an artery already narrowed by atherosclerosis, the same reaction can block blood flow entirely, causing a heart attack, stroke, or sudden loss of blood supply to the leg.

PAD affects an estimated 113 to 200 million people worldwide. The majority of PAD deaths are not from leg complications — they are from heart attacks and strokes caused by the same atherosclerotic process in other arteries. This is why antiplatelet therapy targets the whole cardiovascular system, not just the legs.

How Antiplatelet Drugs Work — Plain Language

There are two main molecular pathways that antiplatelet drugs block:

The COX-1 pathway — aspirin’s target

Aspirin (acetylsalicylic acid) irreversibly disables an enzyme called COX-1 (cyclooxygenase-1). This enzyme normally produces thromboxane A2, a chemical that acts like a fire alarm for platelets — telling them to activate and cluster together. By permanently switching off this alarm in each platelet for its entire lifespan (7 to 10 days), even a small daily dose of aspirin (75–100 mg) provides round-the-clock protection.

A useful analogy: aspirin cuts the wiring between platelets and their “clump together” signal. Even after aspirin is absorbed and eliminated by the body, the platelets it has touched remain disabled.

The P2Y12 pathway — clopidogrel’s and ticagrelor’s target

Clopidogrel and ticagrelor both block a receptor called P2Y12 on the surface of platelets. This receptor normally responds to ADP (adenosine diphosphate), a chemical released when tissue is damaged, which turbocharges platelet activation.

• Clopidogrel is a prodrug — the liver must convert it into its active form. About 25–30% of patients carry a genetic variant in the enzyme CYP2C19 that slows this conversion, reducing clopidogrel’s effectiveness.
• Ticagrelor binds the P2Y12 receptor directly and reversibly, without needing liver activation. Its effect is more predictable across patients and wears off faster when the drug is stopped.

What the Guidelines Say: Aspirin vs Clopidogrel vs Dual Therapy

For symptomatic PAD: clopidogrel is first-line

The ESC/ESVS guidelines recommend:

• Single antiplatelet therapy (SAPT) with clopidogrel 75 mg/day as the preferred first-line agent for patients with symptomatic PAD (Class I recommendation).
• Aspirin 75–100 mg/day is an acceptable alternative if clopidogrel is not tolerated or unavailable.

This preference is backed by the CAPRIE trial — a 1996 randomized controlled trial of over 19,000 patients with atherosclerotic disease. Clopidogrel reduced the combined endpoint of cardiovascular death, heart attack, and stroke by 8.7% relatively compared with aspirin, with the largest relative benefit in the PAD subgroup (CAPRIE Steering Committee, Lancet, 1996, PMID: 8918275).

After peripheral revascularization: short-course dual antiplatelet therapy

After peripheral artery angioplasty and stenting, dual antiplatelet therapy (DAPT) — combining aspirin with clopidogrel — is recommended for 1 to 3 months, after which single antiplatelet therapy is continued long-term.

The COMPASS strategy: a third option for high-risk patients

The COMPASS trial (Eikelboom JW et al., NEJM, 2018, PMID: 28844192) showed that adding low-dose rivaroxaban (2.5 mg twice daily) to aspirin produced a 26% relative reduction in major adverse cardiovascular events and a 46% reduction in major adverse limb events compared with aspirin alone. This strategy carries higher bleeding risk and is reserved for selected high-risk patients after individual benefit-risk discussion.

Ticagrelor in PAD: The EUCLID Trial Evidence

The EUCLID trial (Hiatt WR et al., NEJM, 2017, PMID: 27705249) randomized over 13,800 PAD patients to ticagrelor versus clopidogrel. The result was no significant difference in the primary endpoint. Ticagrelor caused more discontinuations due to side effects — mainly shortness of breath. Current guidelines therefore do not favor ticagrelor over clopidogrel for routine PAD management.

Benefit-Risk Balance: Understanding the Bleeding Trade-Off

All antiplatelet drugs reduce clotting — and therefore increase bleeding risk. The most clinically relevant risks are:

• Gastrointestinal bleeding: black or tarry stools signal a potential bleed requiring urgent attention
• Surgical bleeding: antiplatelet drugs may need a planned pause before elective surgery — always coordinate between your surgeon and prescribing doctor
• Intracranial bleeding: rare but serious, particularly in patients over 75 or with uncontrolled hypertension

In patients with established symptomatic PAD, studies consistently show that the cardiovascular benefit outweighs the bleeding risk across most clinical profiles. A proton pump inhibitor (such as omeprazole or pantoprazole) is often co-prescribed to reduce gastrointestinal bleeding risk.

Never Stop Without Medical Advice

Stopping antiplatelet therapy abruptly — especially in the weeks or months after a stent — can be life-threatening. After a stent is placed inside an artery, the body recognizes it as a foreign object. Antiplatelet drugs are essential while the vessel wall grows over the stent surface. Stopping too early risks acute stent thrombosis — a sudden, complete blockage that can cause a heart attack or major limb ischemia within hours.

Consult your GP or a vascular specialist promptly if:

• You experience unusual bruising, black stools, or prolonged bleeding from minor cuts
• You are unsure whether your current antiplatelet regimen matches your diagnosis and latest guidelines
• You have PAD symptoms (leg pain when walking, slow-healing foot wounds, cold or pale legs) and are not currently on any cardiovascular medication
• You are planning any surgery or major dental procedure

Sources:

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. PMID: 8918275
2. Nordanstig J, et al. ESVS 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb PAD and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2024;67(2):9–96. PMID: 37949800
3. Eikelboom JW, et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2018;377(14):1319–1330. PMID: 28844192
4. Hiatt WR, et al.; EUCLID Trial. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017;376(1):32–40. PMID: 27705249
5. Aboyans V, et al. 2017 ESC Guidelines on Peripheral Arterial Diseases. Eur Heart J. 2018;39(9):763–816. PMID: 28886620

This article is intended for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult your GP or a vascular specialist for any questions relating to your health and medication.